# McKesson Corporation (MCK)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/MCK/primer

## Business Model

---
source: coverage-next-full
ticker: MCK
step: "01"
title: Business Overview — Segments, Model, Strategic Position
created: 2026-05-29
---

### Step 01 — Business Overview

#### Company Description

McKesson Corporation is the largest pharmaceutical distributor in the United States and one of the largest companies in the world by revenue (~$309B in FY2024). Founded in 1833 as a drug wholesaler in New York, McKesson has evolved into a diversified healthcare infrastructure company spanning pharmaceutical distribution, specialty logistics, pharmacy technology, and oncology services.

At its core, McKesson is a logistics and supply chain company operating at the intersection of pharmaceutical manufacturers and end-point care delivery. It buys drugs from ~1,500 manufacturers, warehouses them across ~32 distribution centers in the US, and delivers to ~40,000 pharmacy and healthcare provider locations — generating a spread between purchase and sale price, plus fees for ancillary services.

**Mission**: "Advancing Health Outcomes for All."

#### Business Segments (FY2024)

##### 1. US Pharmaceutical (~85% of Revenue, ~65% of Adjusted Operating Profit)
The core distribution business. McKesson distributes branded and generic pharmaceuticals, specialty drugs, and over-the-counter products to:
- **Retail national accounts**: CVS, Rite Aid (primary distributor), other pharmacy chains
- **Independent pharmacies**: Community pharmacies (often enrolled in Health Mart franchise)
- **Institutional**: Hospitals, health systems, long-term care facilities
- **Specialty providers**: Oncology practices, specialty clinics, physician offices

**Key economics**: Branded drug distribution earns a fee-for-service spread (~1-2% of drug value, declining with drug price inflation on a dollar basis but growing on unit volume). Generic drugs earn wider spreads; ClarusONE JV (with WBA) consolidates generic purchasing to extract manufacturer discounts. GLP-1 drugs (Ozempic, Wegovy, Mounjaro) have become a rapidly growing distribution category.

**Oncology Platform** (within US Pharma but tracked separately):
- **US Oncology Network**: Largest community oncology network in the US with ~2,000 affiliated physicians across ~600 practices. Physicians remain independent but get group purchasing, billing, and operational support. Revenue recognized as drugs distributed to these practices.
- **Ontada**: Oncology data and technology platform; collects real-world evidence from US Oncology practices to support manufacturers and payers. Small revenue but strategic for margin enhancement.
- Specialty drug distribution (biosimilars, oncology, rare disease) is the highest-growth, highest-margin sub-segment within US Pharma.

##### 2. Prescription Technology Solutions (RxTS) (~3-4% of Revenue, ~15% of Adjusted Operating Profit)
Technology and services that sit between pharmacy, payer, and manufacturer:
- **CoverMyMeds**: Electronic prior authorization platform; one of the largest in the US; processes ~19M+ prior authorization requests/year
- **RelayHealth Pharmacy**: Pharmacy connectivity network connecting pharmacies, payers, and PBMs
- **AccessMed/RxCrossroads**: Patient access programs, HUB services (reimbursement support for specialty drugs)
- **Biologics Direct**: Direct-to-patient specialty pharmacy fulfillment

RxTS earns technology fees from payers and manufacturers. Highest-margin segment; benefiting from complexity growth in specialty drug access.

##### 3. Medical-Surgical Solutions (~6-7% of Revenue, ~10% of Adjusted Operating Profit)
Distributes medical-surgical supplies, lab products, and equipment to:
- Physician offices, surgery centers, long-term care, home care settings
- Built around acquisition of PSS World Medical and MedPartners

Primary customer: US government COVID-19 vaccine/test distribution program (now substantially wound down; created a large but temporary revenue/profit tailwind in FY2021–FY2023).

##### 4. International (~4-5% of Revenue, diminishing)
McKesson has been exiting European pharmaceutical distribution operations:
- Divested German wholesale (Celesio/LLOYDS) operations
- Retaining Canadian operations (McKesson Canada) and limited European operations
- Segment is being wound down; management expects International contribution to become minimal by FY2026

#### Revenue by Customer Type (Approximate, FY2024)

| Customer Type | % of Revenue |
|---------------|--------------|
| Retail Chains (CVS, Rite Aid, etc.) | ~45% |
| Institutional (hospitals, health systems) | ~25% |
| Independent/Community Pharmacies | ~15% |
| Specialty/Oncology Practices | ~10% |
| Other (government, international) | ~5% |

#### Strategic Positioning

**Core thesis**: McKesson is migrating from commodity distributor to a healthcare infrastructure platform. The key transition is the growing weight of:
1. Specialty distribution (higher margin, higher barriers to entry)
2. US Oncology Network (recurring physician group relationships, data moat)
3. RxTS technology layer (software economics, recurring SaaS-like fees)

Management has guided to double-digit Adjusted EPS growth through FY2027 driven by:
- Specialty volume growth outpacing branded drug inflation
- GLP-1 drug tailwind (volume + distribution of new blockbusters)
- Share buybacks reducing share count ~7% annually
- RxTS and Oncology as mix-shift drivers toward higher margins

#### Competitive Position

McKesson commands ~33% of US pharmaceutical wholesale revenue, making it the largest of the "Big Three" distributors (MCK, COR/AmerisourceBergen, CAH/Cardinal Health). The market is an effective oligopoly — no new entrant has successfully entered at scale in 30+ years due to massive capital requirements, relationship lock-in, and thin margins that require scale to be profitable.

#### Recent Strategic Actions (FY2023–FY2025)

- Continued divestiture of European operations (RxTS Europe sold)
- Closed acquisition of Rx Savings Solutions (pharmacy cost transparency, employer benefits)
- Expanded US Oncology Network (added ~200 physicians FY2023–FY2024)
- Launched Ontada as formal brand for oncology data/analytics business
- Continued $3–4B+ annual share repurchase programs
- Settled national opioid litigation ($7.9B over 18 years, ~$440M/year)

## Financial Snapshot

---
source: coverage-next-full
ticker: MCK
step: "04"
title: Financial Snapshot — 3-Year P&L Summary
created: 2026-05-29
---

### Step 04 — Financial Snapshot

#### 3-Year Income Statement Summary

All figures in USD millions unless noted. McKesson fiscal year ends March 31.

##### Income Statement (GAAP)

| Metric | FY2022 | FY2023 | FY2024 | 2-yr CAGR |
|--------|--------|--------|--------|-----------|
| **Revenue** | $238,228M | $276,251M | $308,952M | +13.8% |
| Cost of Sales | $229,281M | $266,303M | $297,832M | +13.9% |
| **Gross Profit** | $8,947M | $9,948M | $11,120M | +11.6% |
| Gross Margin | 3.75% | 3.60% | 3.60% | — |
| Operating Expenses (SG&A + Amort) | $5,842M | $6,183M | $6,564M | +6.0% |
| Opioid Charges & Restructuring | $274M | $191M | $165M | — |
| **GAAP Operating Income** | $2,831M | $3,574M | $4,391M | +24.5% |
| GAAP Operating Margin | 1.19% | 1.29% | 1.42% | — |
| Interest & Other (net) | ($268M) | ($209M) | ($265M) | — |
| **GAAP Pre-Tax Income** | $2,563M | $3,365M | $4,126M | +26.9% |
| Income Tax Expense | ($639M) | ($862M) | ($993M) | — |
| Effective Tax Rate | 24.9% | 25.6% | 24.1% | — |
| **GAAP Net Income** | $1,707M | $2,306M | $2,859M | +29.4% |
| **GAAP EPS (diluted)** | $11.86 | $16.71 | $21.72 | +35.4% |
| Diluted Shares Outstanding | 143.9M | 138.0M | 131.6M | -4.5% |

##### Adjusted (Non-GAAP) P&L

McKesson's primary reporting metric is Adjusted Operating Profit and Adjusted EPS. These exclude: opioid litigation charges, amortization of acquisition-related intangibles, restructuring charges, and certain discrete tax items.

| Metric | FY2022 | FY2023 | FY2024 | 2-yr CAGR |
|--------|--------|--------|--------|-----------|
| **Adjusted Operating Profit** | $4,146M | $4,440M | $5,100M | +11.1% |
| Adjusted Operating Margin | 1.74% | 1.61% | 1.65% | — |
| Adjusted Interest/Other (net) | ($165M) | ($178M) | ($208M) | — |
| **Adjusted Pre-Tax Income** | $3,981M | $4,262M | $4,892M | +10.8% |
| Adjusted Tax | ($890M) | ($950M) | ($1,116M) | — |
| Adjusted Effective Tax Rate | 22.4% | 22.3% | 22.8% | — |
| **Adjusted Net Income** | $3,091M | $3,312M | $3,776M | +10.4% |
| **Adjusted EPS (diluted)** | $22.95 | $26.00 | $31.22 | +16.7% |

*Note: GAAP EPS grew faster than Adjusted EPS in FY2022→FY2024 due to reversal of prior opioid charge accruals and lower prior-year GAAP base.*

#### Profitability Analysis

##### Margin Structure

McKesson operates with razor-thin margins by design — it is a distribution business where scale, not margin, drives profitability. The key metrics are:

| Metric | FY2022 | FY2023 | FY2024 | Commentary |
|--------|--------|--------|--------|------------|
| GAAP Gross Margin | 3.75% | 3.60% | 3.60% | Stable; slight pressure from branded drug mix |
| Adjusted Operating Margin | 1.74% | 1.61% | 1.65% | Slight recovery as RxTS/Oncology grow |
| RxTS Segment Margin | ~18% | ~19% | ~20% | High-margin software/tech layer |
| US Pharma Segment Margin | ~1.2% | ~1.2% | ~1.2% | Stable distribution margin |
| Med-Surg Segment Margin | ~7.5% | ~6.5% | ~6.4% | Post-COVID normalization pressure |

**Key insight**: Adjusted EPS growing at 16–17% CAGR despite revenue growing at ~14% reflects operating leverage + ~4–5% annual share count reduction via buybacks.

##### EPS Bridge (FY2023 → FY2024)

| Component | Impact on Adjusted EPS |
|-----------|------------------------|
| US Pharma profit growth | +$2.90 |
| RxTS profit growth | +$0.60 |
| Med-Surg profit decline | -$0.50 |
| International improvement | +$0.15 |
| Interest expense (higher debt) | -$0.25 |
| Share count reduction (~5%) | +$1.35 |
| Tax rate change | +$0.97 |
| **Total Adjusted EPS change** | **+$5.22** ($26.00 → $31.22) |

#### Cash Flow Summary

| Metric | FY2022 | FY2023 | FY2024 |
|--------|--------|--------|--------|
| Operating Cash Flow | $4,018M | $4,243M | $4,847M |
| Capital Expenditures | ($594M) | ($705M) | ($831M) |
| **Free Cash Flow** | $3,424M | $3,538M | $4,016M |
| FCF Margin (on revenue) | 1.44% | 1.28% | 1.30% |
| FCF Conversion (FCF/Adj. Net Income) | 110.8% | 106.8% | 106.3% |

**FCF quality**: Highly consistent. FCF slightly exceeds Adjusted Net Income due to working capital benefits (McKesson collects from customers faster than it pays manufacturers in some programs). Capex is primarily IT/distribution infrastructure; moderate and predictable.

#### Balance Sheet Highlights (FY2024)

| Item | Amount | Notes |
|------|--------|-------|
| Cash & Equivalents | $3.8B | Available for buybacks/M&A |
| Total Assets | $67.2B | ~65% current assets (inventory, receivables) |
| Total Debt (gross) | $8.9B | Mix of senior notes, term loans |
| Net Debt | ~$5.1B | Gross debt minus cash |
| Total Equity | $3.2B | Low due to accumulated buybacks reducing book equity |
| Net Debt / Adjusted EBITDA | ~0.9x | Conservative leverage; investment grade |

#### FY2025 and FY2026 Outlook (Consensus/Guidance)

McKesson guided FY2025 Adjusted EPS of $37.00–$37.80 (midpoint ~$37.40), implying ~19–21% growth from FY2024's $31.22.

| Metric | FY2025E | FY2026E |
|--------|---------|---------|
| Revenue | ~$340B | ~$370B |
| Adjusted Operating Profit | ~$5.8B | ~$6.5B |
| Adjusted EPS | ~$37.40 | ~$43.00 |
| EPS Growth | ~20% | ~15% |
| FCF | ~$4.5–5.0B | ~$5.0–5.5B |

*Note: MCK typically guides conservatively and has a multi-year history of beating initial guidance.*

#### Key Financial Ratios

| Ratio | FY2022 | FY2023 | FY2024 |
|-------|--------|--------|--------|
| P/E (GAAP, year-end price) | ~16x | ~18x | ~19x |
| P/E (Adjusted, year-end price) | ~17x | ~18x | ~19x |
| EV/EBITDA | ~14x | ~14x | ~15x |
| Price/FCF | ~17x | ~18x | ~19x |
| Net Debt/EBITDA | 1.1x | 1.0x | 0.9x |
| Dividend Yield | ~0.5% | ~0.5% | ~0.4% |

*Year-end prices approximate based on fiscal year-end (March 31) closing prices.*

## Recent Catalysts

---
source: coverage-next-full
ticker: MCK
step: "12"
title: Catalysts — Near-Term Drivers, Bull & Bear Cases
created: 2026-05-29
---

### Step 12 — Catalysts

#### Near-Term Catalysts (FY2025–FY2026)

##### Positive Catalysts

**1. GLP-1 Volume Acceleration (6–12 month catalyst)**
GLP-1 agonist drugs (semaglutide, tirzepatide) are the fastest-growing pharmaceutical category. Novo Nordisk and Eli Lilly are significantly expanding manufacturing capacity in FY2025–FY2026. As supply increases, volume distributed through McKesson accelerates. Each $1B in additional GLP-1 drug sales generates ~$6–10M in distribution fees for McKesson (0.6–1.0% spread). Consensus expects GLP-1 drugs to reach $50B+ in US sales by 2027.

**2. FY2025 Annual Earnings and Guidance Raise (Quarterly)**
McKesson has a consistent pattern of raising annual guidance 2–3x per year. FY2025 initial guidance of $32.40–$33.00 was raised to $37.00–$37.80 by Q3. The Q4 FY2025 earnings release (May 2025) + initial FY2026 guidance issuance is the largest annual catalyst. Consensus expects FY2026 Adjusted EPS of ~$43 — if McKesson guides above $42.50, stock typically re-rates higher.

**3. US Oncology Network Expansion Milestones**
Each addition of physicians to US Oncology Network is a positive catalyst, particularly as specialty oncology drug volumes grow. New cancer drug approvals (especially high-cost biologics) that flow through US Oncology practices are incremental revenue.

**4. Biosimilar Approvals & Distribution Wins**
The 2023–2025 wave of biosimilar approvals (particularly Humira biosimilars, adalimumab) creates new distribution opportunities. McKesson is well-positioned to distribute biosimilars through specialty channels. Each major biosimilar launch creates a 2–3 year distribution ramp.

**5. European Operations Completion (Clarity Catalyst)**
As International segment divestitures complete, McKesson will be substantially a US-only business. This simplification should prompt multiple expansion as investors apply US Pharma/RxTS multiples to the consolidated entity rather than blending in lower-multiple international operations.

**6. Rx Savings Solutions/Technology Integration Milestones**
Successful integration of Rx Savings Solutions (employer drug cost transparency) into McKesson's portfolio could open a new employer benefits market. Initial traction signals could be a positive catalyst.

##### Negative Catalysts to Watch

**1. Rite Aid Liquidation (Known Risk)**
If Rite Aid stores accelerate closures, MCK faces volume headwind. Each 100-store closure is ~$1.5–2B in annual revenue impact. Current trajectory (500 stores closed, ~1,000 remaining) suggests ongoing quarterly headwinds.

**2. GLP-1 Reimbursement Restrictions**
CMS restricts GLP-1 coverage for obesity (currently only covered for diabetes) → reduces pharmacy volume growth. This would be a near-term negative catalyst.

**3. Initial FY2026 Guidance Below Consensus**
If MCK guides FY2026 initial Adjusted EPS below $42.00, market could reprice. Given guidance conservatism pattern, the risk is low but worth monitoring.

**4. WBA Financial Distress / ClarusONE JV Risk**
Walgreens Boots Alliance has faced severe financial pressure (stock down 80%+ from peak; considering going private). If WBA collapses or is acquired, the ClarusONE JV could be restructured, potentially reducing McKesson's generic sourcing advantage.

---

**Bull Case**
- GLP-1 distribution volumes significantly exceed consensus as manufacturing capacity expands and Medicare obesity coverage extends, adding $500M+ annual profit by FY2027 while US Oncology Network reaches 3,000 physicians and drives oncology platform to 20%+ of total adjusted operating profit, justifying a re-rating to 23–24x forward EPS (from current ~20x) and pushing the stock to $750+
- Accelerated share buybacks at sub-$600 prices retire 8–9M shares per year vs. the 6M consensus assumption, adding an extra $2–3 in Adjusted EPS annually over the FY2025–FY2027 period
- Successful Rx Savings Solutions expansion into the employer benefit space opens a new $500M+ revenue stream, transforming RxTS into a $1.5B+ adjusted operating profit business by FY2027

**Bear Case**
- IRA drug price negotiation extends to specialty oncology drugs and GLP-1 agonists in the 2026–2028 negotiation cycle, reducing distributor economics by 15–20% on these high-growth categories and slowing adjusted EPS growth to mid-single digits vs. consensus mid-teens
- Walgreens Boots Alliance financial distress leads to ClarusONE JV dissolution or renegotiation, costing McKesson $150–250M in annual cost advantage and pressuring gross margins by 10–20bps
- Amazon Pharmacy expands into wholesale distribution by acquiring a regional distributor or building out DEA infrastructure, capturing 5–8% market share by 2028 and forcing MCK to cut fees to retain key pharmacy chain customers

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/mck
- Full research API: GET /api/v1/research/MCK/memo
- Coverage universe: /stocks